Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OVID 
Ovid Therapeutics Inc (OVID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: OVID (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $3.1
1 Year Target Price $3.1
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.72% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.48M USD | Price to earnings Ratio - | 1Y Target Price 3.1 |
Price to earnings Ratio - | 1Y Target Price 3.1 | ||
Volume (30-day avg) 6 | Beta 0.07 | 52 Weeks Range 0.24 - 1.47 | Updated Date 06/30/2025 |
52 Weeks Range 0.24 - 1.47 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -9653.85% |
Management Effectiveness
Return on Assets (TTM) -31.37% | Return on Equity (TTM) -36.31% |
Valuation
Trailing PE - | Forward PE 1.79 | Enterprise Value -6052728 | Price to Sales(TTM) 39.19 |
Enterprise Value -6052728 | Price to Sales(TTM) 39.19 | ||
Enterprise Value to Revenue 37.79 | Enterprise Value to EBITDA -0.69 | Shares Outstanding 71109504 | Shares Floating 50354780 |
Shares Outstanding 71109504 | Shares Floating 50354780 | ||
Percent Insiders 16.31 | Percent Institutions 55.97 |
Analyst Ratings
Rating 3 | Target Price 3.1 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ovid Therapeutics Inc
Company Overview
History and Background
Ovid Therapeutics Inc. was founded in 2014. It's a biopharmaceutical company focused on developing therapies for rare neurological disorders. They have faced setbacks in clinical trials, leading to strategic shifts.
Core Business Areas
- Rare Neurological Disorders: Focuses on developing and commercializing therapies for rare neurological disorders. Historically developing OV101 (gaboxadol) for Angelman syndrome and other rare disorders.
Leadership and Structure
Ovid has a board of directors and an executive leadership team led by the CEO. Details of the current structure may be found on their investor relations page.
Top Products and Market Share
Key Offerings
- OV101 (gaboxadol): Was Ovid's lead product candidate, intended for Angelman syndrome and other conditions. Development was discontinued after failing to meet endpoints in pivotal trials. No current market share or revenue. Competitors varied depending on the specific indication targeted (e.g., gene therapies, behavioral therapies).
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in rare diseases, is highly competitive and regulated. It requires significant R&D investment, clinical trial success, and regulatory approval. Orphan drug status offers incentives like market exclusivity.
Positioning
Ovid historically positioned itself as a leader in rare neurological disorders. Its competitive advantage centered around its specific molecule, gaboxadol. However, with the failure of OV101 trials, its positioning has shifted.
Total Addressable Market (TAM)
The total addressable market for rare neurological diseases is significant, estimated to be in the billions of dollars. Ovid's position with respect to this TAM is currently limited due to the discontinued development of OV101.
Upturn SWOT Analysis
Strengths
- Expertise in rare neurological disorders (historical)
- Platform for drug development (historical)
Weaknesses
- Failure of pivotal clinical trials
- Limited pipeline
- Dependence on a single molecule (OV101) historically
- Uncertainty about future strategy
Opportunities
- Potential for partnerships or acquisitions
- New drug development platforms
- Emerging understanding of rare neurological disorders
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Funding constraints
Competitors and Market Share
Key Competitors
- AVXS
- BLUE
- CRSP
- IONS
- SRPT
- VRTX
Competitive Landscape
Ovid faces intense competition from larger, well-funded pharmaceutical companies. Its ability to compete depends on its ability to innovate and secure funding.
Growth Trajectory and Initiatives
Historical Growth: Ovid's growth has been limited by clinical trial setbacks.
Future Projections: Future growth projections are highly uncertain and dependent on the company's ability to secure funding, develop new therapies, or be acquired.
Recent Initiatives: Details about recent strategic initiatives can be found in their investor relations section.
Summary
Ovid Therapeutics faces substantial challenges due to setbacks in its clinical trials, particularly with OV101. The company's historical strength was its focus on rare neurological disorders, but its future now depends on securing financing, developing new therapeutic avenues, or being acquired. The firm needs to explore new molecules or strategic partnerships. Success hinges on regaining investor confidence and navigating the competitive pharmaceutical landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company press releases
- Industry reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ovid Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-05-05 | CEO & Chairman Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.ovidrx.com |
Full time employees 23 | Website https://www.ovidrx.com | ||
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.